Alector, Inc. (ALEC)

Market: NASD | Currency: USD

Address: 131 Oyster Point Boulevard

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Show more

📈 Alector, Inc. Historical Chart

📊 Statistics

Analyst 1 Year Price Target: $3.83
Upside/Downside from Analyst Target: 52.12%
Broker Call: 9
Dividend Minimum 3 Year Yield: 0.00%
EPS Growth Range (1Y): 25-50%
Net Income Growth Range (1Y): 25-50%
Revenue Growth Range (1Y): 25-50%
Upcoming Earnings Date: 2025-11-06
EPS Estimate: -0.38

💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for Alector, Inc.

Date	Reported EPS
2025-11-05 (estimated upcoming)	-
2025-08-07	-0.3
2025-05-08	-0.41
2025-02-26	-0.02
2024-11-06	-0.43
2024-08-07	-0.4
2024-05-08	-0.38
2024-02-27	-0.49
2023-11-07	-0.53
2023-08-03	0.02
2023-05-04	-0.55
2023-02-28	-0.63
2022-11-08	-0.56
2022-08-04	0.12
2022-05-05	-0.54
2022-02-24	-0.68
2021-11-04	1.49
2021-08-03	-0.69
2021-05-05	-0.66
2021-02-25	-0.66
2020-11-10	-0.67
2020-08-11	-0.58
2020-05-13	-0.53
2020-03-24	-0.45
2019-11-12	-0.47

📰 Related News & Research

No related articles found for "alector inc".